At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

Journal of Leukocyte Biology

Volumn 94, Issue 6, 2013, Pages 1123-1139

  Norell, Håkan ^a   Moretta, Alessandro ^b   Silva Santos, Bruno ^a   Moretta, Lorenzo ^c  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Blood cancer; Cytomegalovirus; Haploidentical; Hematopoietic stem cell transplantation

Indexed keywords

HLA ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RISK; CYTOMEGALOVIRUS INFECTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REACTIVATION;

BLOOD CANCER; CYTOMEGALOVIRUS; HAPLOIDENTICAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84888812471     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0613312     Document Type: Article

References (232)

1. Locatelli, F., Merli, P., Rutella, S. (2013) At the bedside: innate immunity as an immunotherapy tool for hematological malignancies. J. Leu-koc. Biol. 94, 1141-1157.
2. Daniele, N., Scerpa, M. C, Caniglia, M., Bernardo, M. E., Rossi, C, Ciammetti, C, Palumbo, G., Locatelli, F., Isacchi, G., Zinno, F. (2012) Transplantation in the onco-hematology field: focus on the manipulation of ex/3 and 7Ô T cells. Pathol. Res. Pract. 208, 67-73.
3. Sutlu, T, Alici, E. (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects.J. Intern. Med 266, 154-181.
4. Restifo, N P., Dudley, M. E., Rosenberg, S. A (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281.
5. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99, 16168-16173.
6. Bleakley, M., Riddell, S. R. (2011) Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol. Cell. Biol. 89, 396-407.
7. Dudley, M. E., Gross, C. A, Somerville, R. P., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., Wunderlich, J. R, Kammula, U. S., Sherry, R M., Yang, J. C, Phan, G Q., Hughes, M. S., Laurencot, C. M., Rosenberg, S. A. (2013) Randomized selection design trial evaluating CD8 +-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152-2159.
8. Locatelli, F., Vinti, L., Palumbo, G., Rossi, F., Bertaina, A, Mastronuzzi, A, Bernardo, M. E., Rutella, S., Dellabona, P., Giorgiani, G., Moretta, A, Moretta, L. (2011) Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Pract. Res. Clin. Haematol. 24, 339-349.
9. Klebanoff, C. A, Acquavella, N., Yu, Z., Restifo, N. P. (2011) Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 239, 27-44.
10. Fang, L., Lonsdorf, A. S., Hwang, S. T. (2008) Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128, 2596-2605.
11. Rabinovich, G. A, Gabrilovich, D., Sotomayor, E. M. (2007) Immuno-suppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296.
12. Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C, Cantoni, C, Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A, Moretta, L., Mingari, M. C, Vitale, M. (2009) Melanoma-associated fi-broblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 20847-20852.
13. Gritsenko, P. G., Ilina, O., Friedl, P. (2012) Interstitial guidance of cancer invasion. J. Pathol. 226, 185-199.
14. Pietra, G., Manzini, C, Rivara, S., Vitale, M., Cantoni, C, Petretto, A., Balsamo, M., Conte, R, Benelli, R, Minghelli, S., Solari, N., Gualco, M., Queirolo, P., Moretta, L., Mingari, M. C. (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72, 1407-1415.
15. Smyth, M. J., Teng, M. W., Swann, J., Kyparissoudis, K, Godfrey, D. I., Hayakawa, Y (2006) CD4 + CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587.
16. Lee, J. C, Lee, K M., Kim, D. W., Heo, D. S. (2004) Elevated TGF-/31 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335-7340.
17. Madjd, Z., Spendlove, I., Moss, R, Bevin, S., Pinder, S. E., Watson, N. F., Ellis, I., Durrant, L. G. (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun. 7, 17.
18. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevri-aux, A, Martin, F., Apetoh, L., Rebe, C, Ghiringhelli, F. (2010) 5-Fluo-rouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061.
19. Swanton, C. (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875-4882.
20. Landau, D. A, Carter, S. L., Stojanov, P., McKenna, A, Stevenson, K, Lawrence, M. S., Sougnez, C, Stewart, C, Sivachenko, A., Wang, L., Wan, Y, Zhang, W., Shukla, S. A, Vartanov, A, Fernandes, S. M., Sak-sena, G., Cibulskis, K, Tesar, B., Gabriel, S., Hacohen, N., Meyerson, M., Lander, E. S., Neuberg, D., Brown, J. R, Getz, G., Wu, C. J. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726.
21. Moretta, A., Bottino, C, Vitale, M., Pende, D., Cantoni, C, Mingari, M. C, Biassoni, R, Moretta, L. (2001) Activating receptors and core-ceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223.
22. Lanier, L. L. (2005) NKcell recognition. Annu. Rev. Immunol. 23, 225-274.
23. Bottino, C, Castriconi, R, Pende, D., Rivera, P., Nanni, M., Car-nemolla, B., Cantoni, C, Grassi, J., Marcenaro, S., Reymond, N., Vitale, M., Moretta, L., Lopez, M., Moretta, A. (2003) Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198, 557-567.
24. Castella, B., Vitale, C, Coscia, M., Massaia, M. (2011) Vy9VÔ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell. Mol. Life Sci. 68, 2419-2432.
25. Thedrez, A, Sabourin, C, Gertner, J., Devilder, M. C, Allain-Maillet, S., Fournie, J. J., Scotet, E., Bonneville, M. (2007) Self/non-self discrimination by human -Ô T cells: simple solutions for a complex issue? Immunol. Rev. 215, 123-135.
26. Correia, D. V., Fogli, M., Hudspeth, K, da Silva, M. G., Mavilio, D., Silva-Santos, B. (2011) Differentiation of human peripheral blood VÔ1 + T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992-1001.
27. Moretta, A., Bottino, C, Vitale, M., Pende, D., Biassoni, R., Mingari, M. C, Moretta, L. (1996) Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14, 619-648.
28. Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C, Moretta, A. (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117, 764-771.
29. Moretta, L., Locatelli, F., Pende, D., Sivori, S., Falco, M., Bottino, C, Mingari, M. C, Moretta, A (2011) Human NK receptors: from the molecules to the therapy of high risk leukemias. FEBS Lett. 585, 1563-1567.
30. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K, Shlomchik, W. D., Tosti, A, Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100.
31. Knight, A., Madrigal, A. J., Grace, S., Sivakumaran, J., Kottaridis, P., Mackinnon, S., Travers, P. J., Lowdell, M. W. (2010) The role ofVÔ2-negative yS T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116, 2164-2172.
32. Kuijpers, T. W., Baars, P. A, Dantin, C, van den Burg, M., van Lier, R. A, Roosnek, E. (2008) Human NK cells can control CMV infection in the absence of T cells. Blood 112, 914-915.
33. Scheper, W., van Dorp, S., Kersting, S., Pietersma, F., Lindemans, C, Hol, S., Heijhuurs, S., Sebestyen, Z., Grunder, C, Marcu-Malina, V., Marchant, A, Donner, C, Plachter, B., Vermijlen, D., van Baarle, D., Kuball, J. (2013) 7
34. Trinchieri, G. (1989) Biology of natural killer cells. Adv. Immunol. 47, 187-376.
35. Moretta, L., Ciccone, E., Mingari, M. C, Biassoni, R., Moretta, A. (1994) Human natural killer cells: origin, clonality, specificity, and receptors. Adv. Immunol. 55, 341-380.
36. Moretta, A. (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2, 957-964.
37. Kiessling, R., Petranyi, G., Klein, G., Wigzel, H. (1975) Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int. J. Cancer 15, 933-940.
38. Lanier, L. L., Le, A. M., Phillips, J. H., Warner, N. L., Babcock, G. F. (1983) Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J. Immunol. 131, 1789-1796.
39. Perussia, B., Starr, S., Abraham, S., Fanning, V., Trinchieri, G. (1983) Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J. Immunol. 130, 2133-2141.
40. Perussia, B., Acuto, O., Terhorst, C, Faust, J., Lazarus, R., Fanning, V., Trinchieri, G. (1983) Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J. Immunol. 130, 2142-2148.
41. Veeramani, S., Wang, S. Y., Dahle, C, Blackwell, S., Jacobus, L., Knut-son, T., Button, A, Link, B. K, Weiner, G. J. (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118, 3347-3349.
42. Lanier, L. L., Chang, C, Azuma, M., Ruitenberg, J. J., Hemperly, J. J., Phillips, J. H. (1991) Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J. Immunol. 146, 4421-4426.
43. Caligiuri, M. A. (2008) Human natural killer cells. Blood 112, 461-469.
44. Ljunggren, H. G., Karre, K. (1990) In search of the 'missing self: MHC molecules and NK cell recognition. Immunol. Today 11, 237-244.
45. Karre, K., Ljunggren, H. G., Piontek, G., Kiessling, R. (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678.
46. Moretta, A, Bottino, C, Pende, D., Tripodi, G., Tambussi, G, Viale, O., Orengo, A, Barbaresi, M., Merli, A, Ciccone, E., et al. (1990) Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.J. Exp. Med 172, 1589-1598.
47. Moretta, A, Tambussi, G, Bottino, C, Tripodi, G, Merli, A, Ciccone, E., Pan-taleo, G, Moretta, L. (1990) A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function.J. Exp. Med 171, 695-714.
48. Moretta, A., Vitale, M., Bottino, C, Orengo, A. M., Morelli, L., Augugli-aro, R., Barbaresi, M., Ciccone, E., Moretta, L. (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604.
49. Wagtmann, N., Biassoni, R., Cantoni, C, Verdiani, S., Malnati, M. S., Vitale, M., Bottino, C, Moretta, L., Moretta, A, Long, E. O. (1995) Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2, 439-449.
50. Ciccone, E., Pende, D., Viale, O., Than, A, Di Donato, C, Orengo, A M., Biassoni, R., Verdiani, S., Amoroso, A, Moretta, A, et al. (1992) Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J. Exp. Med. 176, 963-971.
51. Vitale, M., Sivori, S., Pende, D., Moretta, L., Moretta, A. (1995) Coex-pression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells. Proc. Natl. Acad. Sci. USA 92, 3536-3540.
52. Pende, D., Biassoni, R., Cantoni, C, Verdiani, S., Falco, M., di Donato, C, Accame, L., Bottino, C, Moretta, A, Moretta, L. (1996) The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disul-phide-linked dimer. J. Exp. Med 184, 505-518.
53. Vitale, M., Sivori, S., Pende, D., Augugliaro, R., Di Donato, C, Amoroso, A, Malnati, M., Bottino, C, Moretta, L., Moretta, A (1996) Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones. Proc. Natl Acad Sci USA 93, 1453-1457.
54. Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro, R., Bottino, C, Moretta, L. (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J. Exp. Med. 182, 875-884.
55. Biassoni, R., Cantoni, C, Falco, M., Verdiani, S., Bottino, C, Vitale, M., Conte, R., Poggi, A, Moretta, A, Moretta, L. (1996) The human leukocyte antigen (HLA)-Cspecific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J. Exp. Med 183, 645-650.
56. Lopez-Botet, M., Perez-Villar, J. J., Carretero, M., Rodriguez, A, Mel-ero, I., Bellon, T., Llano, M., Navarro, F. (1997) Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol. Rev. 155, 165-174.
57. Braud, V M., Allan, D. S., O'Callaghan, C. A, Soderstrom, K, D'Andrea, A, Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., McMichael, A. J. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799.
58. Ciccone, E., Viale, O., Pende, D., Malnati, M., Biassoni, R., Melioli, G., Moretta, A., Long, E. O., Moretta, L. (1988) Specific lysis of allogeneic cells after activation of CD3- lymphocytes in mixed lymphocyte culture. J. Exp. Med. 168, 2403-2408.
59. Mingari, M. C, Vitale, C, Cambiaggi, A, Schiavetti, F., Melioli, G., Ferrini, S., Poggi, A (1995) Cytolytic T lymphocytes displaying natural killer (NK)-like activity expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int. Immunol. 7, 697-703.
60. Malmberg, K. J., Levitsky, V, Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K, Rabbani, H., Moretta, A, Soderstrom, K, Levitskaya, J., Kiessling, R. (2002) IFN-7 protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110, 1515-1523.
61. Mingari, M. C, Schiavetti, F., Ponte, M., Vitale, C, Maggi, E., Romag-nani, S., Demarest, J., Pantaleo, G., Fauci, A. S., Moretta, L. (1996) Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc. Natl. Acad. Sci. USA 93, 12433-12438.
62. Mingari, M. C, Moretta, A, Moretta, L. (1998) Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today 19, 153-157.
63. Pietra, G., Romagnani, C, Falco, M., Vitale, M., Castriconi, R., Pende, D., Millo, E., Anfossi, S., Biassoni, R., Moretta, L., Mingari, M. C. (2001) The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR ex//3-mediated recognition. Eur. J. Immunol. 31, 3687-3693.
64. Romagnani, C, Pietra, G., Falco, M., Millo, E., Mazzarino, P., Biassoni, R., Moretta, A., Moretta, L., Mingari, M. C. (2002) Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc. Natl. Acad. Sci. USA 99, 11328-11333.
65. Moretta, L., Romagnani, C, Pietra, G., Moretta, A, Mingari, M. C. (2003) NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol. 24, 136-143.
66. Pietra, G., Romagnani, C, Mazzarino, P., Falco, M., Millo, E., Moretta, A, Moretta, L., Mingari, M. C. (2003) HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc. Natl. Acad. Sci. USA 100, 10896-10901.
67. Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C, Moretta, L., Moretta, A. (1997) p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 186, 1129-1136.
68. Pessino, A, Sivori, S., Bottino, C, Malaspina, A, Morelli, L., Moretta, L., Biassoni, R., Moretta, A. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953-960.
69. Vitale, M., Bottino, C, Sivori, S., Sanseverino, L., Castriconi, R., Mar-cenaro, E., Augugliaro, R., Moretta, L., Moretta, A. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187, 2065-2072.
70. Cantoni, C, Bottino, C, Vitale, M., Pessino, A, Augugliaro, R., Malaspina, A, Parolini, S., Moretta, L., Moretta, A, Biassoni, R. (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189, 787-796.
71. Pende, D., Parolini, S., Pessino, A, Sivori, S., Augugliaro, R., Morelli, L., Mar-cenaro, E., Accame, L., Malaspina, A, Biassoni, R., Bottino, C, Moretta, L., Moretta, A (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med 190, 1505-1516.
72. Moretta, L., Biassoni, R., Bottino, C, Mingari, M. C, Moretta, A. (2000) Human NK-cell receptors. Immunol. Today 21, 420-422.
73. Brandt, C. S., Baratin, M., Yi, E. C, Kennedy, J., Gao, Z., Fox, B., Hal-deman, B., Ostrander, C. D., Kaifu, T., Chabannon, C, Moretta, A., West, R., Xu, W., Vivier, E., Levin, S. D. (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503.
74. Pogge von Strandmann, E., Simhadri, V. R, von Tresckow, B., Sasse, S., Rein-ers, K S., Hansen, H. P., Rothe, A, Boll, B., Simhadri, V. L., Borchmann, P., McKinnon, P. J., Hallek, M., Engert, A (2007) Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974.
75. Arnon, T. I., Achdout, H., Levi, O., Markel, G., Saleh, N., Katz, G., Ga-zit, R, Gonen-Gross, T., Hanna, J., Nahari, E., Porgador, A, Honig-man, A, Plachter, B., Mevorach, D., Wolf, D. G., Mandelboim, O. (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 6, 515-523.
76. Groh, V., Wu, J., Yee, C, Spies, T. (2002) Tumour-derived soluble MIC li-gands impair expression of NKG2D and T-cell activation. Nature419, 734-738.
77. Nakajima, H., Cella, M., Langen, H., Friedlein, A, Colonna, M. (1999) Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur. J. Immunol. 29, 1676-1683.
78. Sivori, S., Falco, M., Della Chiesa, M., Carlomagno, S., Vitale, M., Moretta, L., Moretta, A. (2004) CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 101, 10116-10121.
79. Marcenaro, E., Ferranti, B., Falco, M., Moretta, L., Moretta, A (2008) Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int. Immunol. 20, 1155-1167.
80. Sivori, S., Carlomagno, S., Falco, M., Romeo, E., Moretta, L., Moretta, A. (2011) Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in hap-loidentical HSCT. Blood 117, 4284-4292.
81. Vacca, P., Martini, S., Garelli, V, Passalacqua, G., Moretta, L., Mingari, M. C. (2013) NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur. J. Immunol. 43, 550-561.
82. Castriconi, R, Cantoni, C, Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R, Biassoni, R., Bottino, C, Moretta, L., Moretta, A. (2003) Transforming growth factor /3 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100, 4120-4125.
83. Mamessier, E., Sylvain, A, Thibult, M. L., Houvenaeghel, G, Jacquemier, J., Castellano, R, Goncalves, A, Andre, P., Romagne, F., Thibault, G, Viens, P., Birnbaum, D., Bertucci, F., Moretta, A, Olive, D. (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.J. Clin. Invest. 121, 3609-3622.
84. Della Chiesa, M., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C, Conte, R, Moretta, L., Moretta, A, Vitale, M. (2006) The trypto-phan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118-4125.
85. Spaggiari, G. M., Capobianco, A, Abdelrazik, H., Becchetti, F., Mingari, M. C, Moretta, L. (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxyge-nase and prostaglandin E2. Blood 111, 1327-1333.
86. Graf, T. (2002) Differentiation plasticity of hematopoietic cells. Blood 99, 3089-3101.
87. Osawa, M., Hanada, K, Hamada, H., Nakauchi, H. (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273, 242-245.
88. Grzywacz, B., Kataria, N., Sikora, M., Oostendorp, R. A, Dzierzak, E. A, Blazar, B. R, Miller, J. S., Verneris, M. R (2006) Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108, 3824-3833.
89. Mrozek, E., Anderson, P., Caligiuri, M. A. (1996) Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34 + hematopoietic progenitor cells. Blood 87, 2632-2640.
90. Gascoyne, D. M., Long, E., Veiga-Fernandes, H., de Boer, J., Williams, O., Seddon, B., Coles, M., Kioussis, D., Brady, H. J. (2009) The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat. Immunol. 10, 1118-1124.
91. Aliahmad, P., de la Torre, B., Kaye, J. (2010) Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat. Immunol. 11, 945-952.
92. Yun, S., Lee, S. H., Yoon, S. R, Kim, M. S., Piao, Z. H., Myung, P. K, Kim, T. D., Jung, H., Choi, I. (2011) TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol. Lett. 136, 29-36.
93. Vitale, C, Cottalasso, F., Montaldo, E., Moretta, L., Mingari, M. C. (2008) Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. Int. Immunol. 20, 565-575.
94. Grzywacz, B., Kataria, N., Blazar, B. R, Miller, J. S., Verneris, M. R (2011) Natural killer-cell differentiation by myeloid progenitors. Blood 117, 3548-3558.
95. Perez, S. A, Sotiropoulou, P. A, Gkika, D. G., Mahaira, L. G., Niar-chos, D. K, Gritzapis, A. D., Kavalakis, Y G., Antsaklis, A. I., Baxevanis, C. N., Papamichail, M. (2003) A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 101, 3444-3450.
96. Mingari, M. C, Poggi, A, Biassoni, R., Bellomo, R., Ciccone, E., Pella, N., Morelli, L., Verdiani, S., Moretta, A, Moretta, L. (1991) In vitro proliferation and cloning of CD3- CD16+ cells from human thymo-cyte precursors. J. Exp. Med. 174, 21-26.
97. Freud, A. G., Caligiuri, M. A. (2006) Human natural killer cell development. Immunol. Rev. 214, 56-72.
98. Freud, A G., Yokohama, A, Becknell, B., Lee, M. T., Mao, H. C, Ferketich, A. K., Caligiuri, M. A (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med 203, 1033-1043.
99. Vacca, P., Moretta, L., Moretta, A, Mingari, M. C. (2011) Origin, phe-notype and function of human natural killer cells in pregnancy. Trends Immunol. 32, 517-523.
100. Vacca, P., Vitale, C, Montaldo, E., Conte, R, Cantoni, C, Fulcheri, E., Darretta, V, Moretta, L., Mingari, M. C. (2011) CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc. Natl. Acad. Sci. USA 108, 2402-2407.
101. Moroso, V, Famili, F., Papazian, N, Cupedo, T, van der Laan, L. J., Kaze-mier, G, Metselaar, H J., Kwekkeboom, J. (2011) NK cells can generate from precursors in the adult human liver. Eur. J. Immunol 41, 3340-3350.
102. Chinen, H., Matsuoka, K, Sato, T., Kamada, N., Okamoto, S., Hisa-matsu, T., Kobayashi, T., Hasegawa, H., Sugita, A, Kinjo, F., Fujita, J., Hibi, T. (2007) Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastro-enterology 133, 559-573.
103. Montaldo, E., Del Zotto, G., Della Chiesa, M., Mingari, M. C, De Maria, A, Moretta, L. (2013) Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 83, 702-713.
104. Spits, H., Cupedo, T. (2012) Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647-675.
105. Cella, M., Fuchs, A, Vermi, W., Facchetti, F., Otero, K, Lennerz, J. K, Doherty, J. M., Mills, J. C, Colonna, M. (2009) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725.
106. Hayday, A. C. (2000) 7Ô Cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18, 975-1026.
107. Pont, F., Familiades, J., Dejean, S., Fruchon, S., Cendron, D., Poupot, M., Poupot, R, L'Faqihi-Olive, F., Prade, N., Ycart, B., Fournie, J. J. (2012) The gene expression profile of phosphoantigen-specific human y8 T lymphocytes is a blend of ex/3 T-cell and NK-cell signatures. Eur. J. Immunol. 42, 228-240.
108. Morita, C. T., Jin, C, Sarikonda, G., Wang, H. (2007) Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vy2VÔ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215, 59-76.
109. Gober, H. J., Kistowska, M., Angman, L., Jeno, P., Mori, L., De Libero, G (2003) Human T cell receptor 7Ô cells recognize endogenous me-valonate metabolites in tumor cells.J. Exp. Med. 197, 163-168.
110. Bukowski, J. F., Morita, C. T., Tanaka, Y, Bloom, B. R, Brenner, M. B., Band, H. (1995) V 7 2V 8 2 TCR-dependent recognition of non-pep-tide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 154, 998-1006.
111. Nedellec, S., Bonneville, M., Scotet, E. (2010) Human Vy9VÔ2 T cells: from signals to functions. Semin. Immunol. 22, 199-206.
112. Vavassori, S., Kumar, A, Wan, G. S., Ramanjaneyulu, G. S., Cavallari, M., El Daker, S., Beddoe, T., Theodossis, A, Williams, N. K, Gostick, E., Price, D. A, Soudamini, D. U., Voon, K K, Olivo, M., Rossjohn, J., Mori, L., De Libero, G. (2013) Butyrophilin 3A1 binds phosphorylated antigens and stimulates human 7Ô T cells. Nat. Immunol. 14, 908-916.
113. Harly, C, Guillaume, Y, Nedellec, S., Peigne, C. M., Monkkonen, H., Monkkonen, J., Li, J., Kuball, J., Adams, E. J., Netzer, S., Dechanet-Mer-ville, J., Leger, A, Herrmann, T., Breathnach, R, Olive, D., Bonneville, M., Scotet, E. (2012) Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human 7Ô T-cell subset. Blood 120, 2269-2279.
114. Wrobel, P., Shojaei, H., Schittek, B., Gieseler, F., Wollenberg, B., Kalthoff, H., Kabelitz, D., Wesch, D. (2007) Lysis of a broad range of epithelial tumour cells by human 7 8 T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand. J. Immunol. 66, 320-328.
115. Toutirais, O., Cabillic, F., Le Friec, G, Salot, S., Loyer, P., Le Gallo, M., De-sille, M., de La Pintiere, C. T, Daniel, P., Bouet, F., Catros, V (2009) DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vy9VÔ2 T cells. Eur. J. Immunol. 39, 1361-1368.
116. Carena, I., Shamshiev, A., Donda, A., Colonna, M., Libero, G. D. (1997) Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-7/5 stimulated by nonpeptidic ligands. J. Exp. Med. 186, 1769-1774.
117. Correia, D. V., Lopes, A, Silva-Santos, B. (2013) Tumor cell recognition by 7Ô T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoim-munology 2, e22892.
118. Das, H., Groh, V., Kuijl, C, Sugita, M., Morita, C. T., Spies, T., Bu-kowski, J. F. (2001) MICA engagement by human V72VÔ2 T cells enhances their antigen-dependent effector function. Immunity 15, 83-93.
119. Gomes, A. Q., Correia, D. V., Silva-Santos, B. (2007) Non-classical major histocompatibility complex proteins as determinants of tumour im-munosurveillance. EMBO Rep. 8, 1024-1030.
120. Raulet, D. H., Guerra, N. (2009) Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9, 568-580.
121. Girardi, M., Oppenheim, D. E., Steele, C R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., Hayday, A. C. (2001) Regulation of cutaneous malignancy by 7Ô T cells. Science 294, 605-609.
122. Strid, J., Roberts, S. J., Filler, R B., Lewis, J. M., Kwong, B. Y., Schpero, W., Kaplan, D. H., Hayday, A. C, Girardi, M. (2008) Acute upregula-tion of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat. Immunol. 9, 146-154.
123. Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R E., Girardi, M., Hayday, A. C (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6, 928-937.
124. Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A, Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. M., Raulet, D. H. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571-580.
125. Gomes, A. Q., Correia, D. V., Grosso, A. R, Lanca, T., Ferreira, C, Lacerda, J. F., Barata, J. T., Silva, M. G., Silva-Santos, B. (2010) Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood y8 T cells. Haematologica 95, 1397-1404.
126. Lanca, T., Correia, D. V., Moita, C. F., Raquel, H., Neves-Costa, A, Ferreira, C, Ramalho, J. S., Barata, J. T., Moita, L. F., Gomes, A. Q., Silva-Santos, B. (2010) The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to 7Ô T-cell cytotoxicity. Blood 115, 2407-2411.
127. Kong, Y, Cao, W., Xi, X., Ma, C, Cui, L., He, W. (2009) The NKG2D ligand ULBP4 binds to TCR79/Ô2 and induces cytotoxicity to tumor cells through both TCR.Ô and NKG2D. Blood 114, 310-317.
128. Poggi, A, Venturino, C, Catellani, S., Clavio, M., Miglino, M., Gobbi, M., Steinle, A, Ghia, P., Stella, S., Caligaris-Cappio, F., Zocchi, M. R (2004) VÔ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 64, 9172-9179.
129. Catellani, S., Poggi, A, Bruzzone, A., Dadati, P., Ravetti, J. L., Gobbi, M., Zocchi, M. R. (2007) Expansion of VÔ1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 109, 2078-2085.
130. Gertner-Dardenne, J., Castellano, R, Mamessier, E., Garbit, S., Koch-bati, E., Etienne, A, Charbonnier, A, Collette, Y, Vey, N., Olive, D. (2012) Human V79VÔ2 T cells specifically recognize and kill acute my-eloid leukemic blasts. J. Immunol. 188, 4701-4708.
131. Shibuya, A., Campbell, D., Hannum, C, Yssel, H., Franz-Bacon, K, Mc-Clanahan, T., Kitamura, T., Nicholl, J., Sutherland, G. R, Lanier, L. L., Phillips, J. H. (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4, 573-581.
132. Pende, D., Bottino, C, Castriconi, R, Cantoni, C, Marcenaro, S., Rivera, P., Spaggiari, G M., Dondero, A, Carnemolla, B., Reymond, N, Mingari, M. C, Lopez, M., Moretta, L., Moretta, A (2005) PVR (CD155) and nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 42, 463-469.
133. Pende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobi-anco, A, Falco, M., Lanino, E., Pierri, I., Zambello, R, Bacigalupo, A, Mingari, M. C, Moretta, A, Moretta, L. (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112). Blood 105, 2066-2073.
134. Carlsten, M., Bjorkstrom, N. K, Norell, H., Bryceson, Y, van Hall, T., Baumann, B. C, Hanson, M., Schedvins, K, Kiessling, R, Ljunggren, H. G., Malmberg, K J. (2007) DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67, 1317-1325.
135. Carlsten, M., Norell, H., Bryceson, Y T., Poschke, I., Schedvins, K, Ljunggren, H. G., Kiessling, R, Malmberg, K. J. (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183, 4921-4930.
136. Carlsten, M., Baumann, B. C, Simonsson, M., Jadersten, M., Forsblom, A M., Hammarstedt, C, Bryceson, Y T., Ljunggren, H. G., Hellstrom-Lindberg, E., Malmberg, K. J. (2010) Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 24, 1607-1616.
137. Knight, A., Mackinnon, S., Lowdell, M. W. (2012) Human VÔ1 7-Ô T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14, 1110-1118.
138. Croxford, J. L., Tang, M. L., Pan, M. F., Huang, C W., Kamran, N., Phua, C. M, Chng, W. J., Ng, S. B., Raulet, D. H., Gasser, S. (2013) ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 121, 2512-2521.
139. Hudspeth, K, Silva-Santos, B., Mavilio, D. (2013) Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front. Immunol. 4, 69.
140. Couzi, L., Pitard, V., Sicard, X., Garrigue, I., Hawchar, O., Merville, P., Moreau, J. F., Dechanet-Merville, J. (2012) Antibody-dependent anti-cytomegalovirus activity of human 7Ô T cells expressing CD16 (Fc7RIIIa). Blood 119, 1418-1427.
141. Gertner-Dardenne, J., Bonnafous, C, Bezombes, C, Capietto, A H., Scagli-one, V., Ingoure, S., Cendron, D., Gross, E., Lepage, J. F., Quillet-Mary, A, Ysebaert, L., Laurent, G, Sicard, H., Fournie, J. J. (2009) Bromohydrin pyro-phosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113, 4875-4884.
142. Tokuyama, H., Hagi, T., Mattarollo, S. R, Morley, J., Wang, Q., So, H. F., Moriyasu, F., Nieda, M., Nicol, A. J. (2008) V 7 9 V 8 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int. J. Cancer 122, 2526-2534.
143. Braza, M. S., Klein, B., Fiol, G., Rossi, J. F. (2011) 7Ô T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica 96, 400-407.
144. Meraviglia, S., Caccamo, N., Guggino, G., Tolomeo, M., Siragusa, S., Stassi, G., Dieli, F. (2010) Optimizing tumor-reactive 7Ô T cells for antibody-based cancer immunotherapy. Curr. Mol. Med. 10, 719-726.
145. Liu, Z., Eltoum, I. E., Guo, B., Beck, B. H., Cloud, G. A., Lopez, R D. (2008) Protective immunosurveillance and therapeutic antitumor activity of 7Ô T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180, 6044-6053.
146. Gao, Y, Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., Yin, Z. (2003) 7 8 T cells provide an early source of inter-feron gamma in tumor immunity. J. Exp. Med. 198, 433-442.
147. Street, S. E., Hayakawa, Y, Zhan, Y, Lew, A. M., MacGregor, D., Ja-mieson, A. M., Diefenbach, A, Yagita, H., Godfrey, D. I., Smyth, M. J. (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and 7Ô T cells. J. Exp. Med. 199, 879-884.
148. Gomes, A. Q., Martins, D. S., Silva-Santos, B. (2010) Targeting 7Ô T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 70, 10024-10027.
149. Hannani, D., Ma, Y, Yamazaki, T., Dechanet-Merville, J., Kroemer, G., Zitvogel, L. (2012) Harnessing 7Ô T cells in anticancer immunother-apy. Trends Immunol. 33, 199-206.
150. Cornelissen, J. J., Gratwohl, A, Schlenk, R. F., Sierra, J., Bornhauser, M., Juliusson, G., Racil, Z., Rowe, J. M., Russell, N., Mohty, M., Lowen-berg, B., Socie, G., Niederwieser, D., Ossenkoppele, G. J. (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat. Rev. Clin. Oncol. 9, 579-590.
151. Gladstone, D. E., Fuchs, E. (2012) Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr. Opin. Oncol. 24, 176-181.
152. Gupta, V., Tallman, M. S., Weisdorf, D. J. (2011) Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117, 2307-2318.
153. Jabbour, E., Cortes, J., Santos, F. P., Jones, D., O'Brien, S., Rondon, G., Popat, U., Giralt, S., Kebriaei, P., Jones, R B., Kantarjian, H., Cham-plin, R, de Lima, M. (2011) Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117, 3641-3647.
154. Huang, X. J. (2008) Current status of haploidentical stem cell transplantation for leukemia. J. Hematol. Oncol. 1, 27.
155. Aversa, F., Tabilio, A, Terenzi, A, Velardi, A, Falzetti, F., Giannoni, C, Iacucci, R, Zei, T., Martelli, M. P., Gambelunghe, C, et al. (1994) Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84, 3948-3955.
156. Aversa, F., Tabilio, A, Velardi, A., Cunningham, I., Terenzi, A, Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C, Latini, P., Reisner, Y, Martelli, M. F. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339, 1186-1193.
157. Ciurea, S. O., Mulanovich, V., Saliba, R M., Bayraktar, U. D., Jiang, Y, Bassett, R., Wang, S. A, Konopleva, M., Fernandez-Vina, M., Montes, N., Bosque, D., Chen, J., Rondon, G., Alatrash, G., Alousi, A, Bashir, Q., Korbling, M., Qazilbash, M., Parmar, S., Shpall, E., Nieto, Y, Hosing, C, Kebriaei, P., Khouri, I., Popat, U., de Lima, M., Champlin, R. E. (2012) Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 18, 1835-1844.
158. Solomon, S. R., Sizemore, C. A., Sanacore, M., Zhang, X., Brown, S., Holland, H. K, Morris, L. E., Bashey, A. (2012) Haploidentical transplantation using T cell replete peripheral blood stem cells and myelo-ablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol. Blood Marrow Transplant. 18, 1859-1866.
159. Huang, X. J., Liu, D. H., Liu, K. Y., Xu, L. P., Chen, H., Han, W., Chen, Y. H., Zhang, X. H., Lu, D. P. (2009) Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol. Blood Marrow Transplant. 15, 257-265.
160. Luznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A, Piantadosi, S., Kaup, M., Ambinder, R. F., Huff, C. A, Matsui, W., Bolanos-Meade, J., Borrello, I., Powell, J. D., Harrington, E., Warnock, S., Flowers, M., Brodsky, R. A, Sandmaier, B. M., Storb, R. F., Jones, R. J., Fuchs, E. J. (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using non-myeloablative conditioning and high-dose, posttransplantation cyclo-phosphamide. Biol. Blood Marrow Transplant. 14, 641-650.
161. Aversa, F., Terenzi, A, Tabilio, A, Falzetti, F., Carotti, A, Ballanti, S., Felicini, R., Falcinelli, F., Velardi, A, Ruggeri, L., Aloisi, T., Saab, J. P., Santucci, A, Perruccio, K, Martelli, M. P., Mecucci, C, Reisner, Y, Martelli, M. F. (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23, 3447-3454.
162. Ciccone, E., Pende, D., Viale, O., Di Donato, C, Tripodi, G., Orengo, A M., Guardiola, J., Moretta, A., Moretta, L. (1992) Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J. Exp. Med. 175, 709-718.
163. Ciccone, E., Pende, D., Vitale, M., Nanni, L., Di Donato, C, Bottino, C. Morelli, L., Viale, O., Amoroso, A, Moretta, A, et al. (1994) Self class I molecules protect normal cells from lysis mediated by autolo-gous natural killer cells. Eur. J. Immunol. 24, 1003-1006.
164. Colonna, M., Samaridis, J. (1995) Cloning of immunoglobulin-super-family members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268, 405-408.
165. Chen, X., Hale, G. A, Barfield, R., Benaim, E., Leung, W. H., Knowles, J., Horwitz, E. M., Woodard, P., Kasow, K, Yusuf, U., Behm, F. G., Hayden, R. T., Shurtleff, S. A, Turner, V, Srivastava, D. K, Handgret-inger, R. (2006) Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br. J. Haematol. 135, 524-532.
166. Bethge, W. A, Haegele, M., Faul, C, Lang, P., Schumm, M., Born-hauser, M., Handgretinger, R., Kanz, L. (2006) Haploidentical alloge-neic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low tox-icity. Exp. Hematol. 34, 1746-1752.
167. Federmann, B., Bornhauser, M., Meisner, C, Kordelas, L., Beelen, D. W., Stuhler, G., Stelljes, M., Schwerdtfeger, R., Christopeit, M., Behre, G., Faul, C, Vogel, W., Schumm, M., Handgretinger, R., Kanz, L., Bethge, W. A. (2012) Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced in tensity conditioning: a phase II study. Haematologica 97, 1523-1531.
168. Handgretinger, R., Chen, X., Pfeiffer, M., Mueller, I., Feuchtinger, T., Hale, G. A, Lang, P. (2007) Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann. N. Y. Acad. Sci. 1106, 279-289.
169. Oevermann, L., Lang, P., Feuchtinger, T., Schumm, M., Teltschik, H. M., Schlegel, P., Handgretinger, R. (2012) Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann. N. Y. Acad. Sci. 1266, 161-170.
170. Federmann, B., Hagele, M., Pfeiffer, M., Wirths, S., Schumm, M., Faul, C, Vogel, W., Handgretinger, R., Kanz, L., Bethge, W. A. (2011) Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 25, 121-129.
171. Guinan, E., Luzmik, L., Handgretinger, R., Woolfrey, A. (2010) Preservation of immune repertoire by selective depletion of haploidentical grafts. Biol. Blood Marrow Transplant. 16, S68-S74.
172. Handgretinger, R. (2012) New approaches to graft engineering for haploidentical bone marrow transplantation. Semin. Oncol. 39, 664-673.
173. Mielke, S., Nunes, R., Rezvani, K, Fellowes, V. S., Venne, A, Solomon, S. R., Fan, Y, Gostick, E., Price, D. A, Scotto, C, Read, E. J., Barrett, A. J. (2008) A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, 4392-4402.
174. Rutella, S., Locatelli, F. (2011) Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation. Am. J. Transl. Res. 3, 404-421.
175. Handgretinger, R. (2012) Negative depletion of CD3(+) and TcRa/3(+) T cells. Curr. Opin. Hematol. 19, 434-439.
176. Locatelli, F., Pende, D., Mingari, M. C, Bertaina, A, Falco, M., Moretta, A, Moretta, L. (2013) Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front. Immunol. 4, 15.
177. Chaleff, S., Otto, M., Barfield, R. C, Leimig, T., Iyengar, R., Martin, J., Holiday, M., Houston, J., Geiger, T., Huppert, V, Handgretinger, R. (2007) A large-scale method for the selective depletion of ex/3 T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 9, 746-754.
178. Godder, K. T., Henslee-Downey, P. J., Mehta, J., Park, B. S., Chiang, K Y, Abhyankar, S., Lamb, L. S. (2007) Long term disease-free survival in acute leukemia patients recovering with increased 7Ô T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751-757.
179. Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Mon-tagna, D., Romeo, E., Cognet, C, Martinetti, M., Maccario, R., Mingari, M. C, Vivier, E., Moretta, L., Locatelli, F., Moretta, A. (2009) Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113, 3119-3129.
180. Chewning, J. H., Gudme, C. N., Hsu, K. C, Selvakumar, A, Dupont, B. (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J. Immunol. 179, 854-868.
181. Cognet, C, Farnarier, C, Gauthier, L., Frassati, C, Andre, P., Magerus-Chatinet, A, Anfossi, N., Rieux-Laucat, F., Vivier, E., Schleinitz, N. (2010) Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin. Immunol. 135, 26-32.
182. Murphy, W. J., Kumar, V., Bennett, M. (1987) Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J. Exp. Med. 166, 1499-1509.
183. Murphy, W. J., Kumar, V., Bennett, M. (1987) Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J. Exp. Med. 165, 1212-1217.
184. Bennett, M. (1987) Biology and genetics of hybrid resistance. Adv. Immunol. 41, 333-445.
185. Cooley, S., Weisdorf, D. J., Guethlein, L. A, Klein, J. P., Wang, T., Le, C. T., Marsh, S. G., Geraghty, D., Spellman, S., Haagenson, M. D., Lad-ner, M., Trachtenberg, E., Parham, P., Miller, J. S. (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116, 2411-2419.
186. Carding, S. R., Egan, P. J. (2002) 7Ô T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336-345.
187. Kunzmann, V, Smetak, M., Kimmel, B., Weigang-Koehler, K, Goe-beler, M., Birkmann, J., Becker, J., Schmidt-Wolf, I. G., Einsele, H., Wil-helm, M. (2012) Tumor-promoting versus tumor-antagonizing roles of y8 T cells in cancer immunotherapy: results from a prospective phase I/II trial. J. Immunother. 35, 205-213.
188. Burke, S., Lakshmikanth, T., Colucci, F., Carbone, E. (2010) New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 31, 339-345.
189. Fisch, P., Malkovsky, M., Kovats, S., Sturm, E., Braakman, E., Klein, B. S., Voss, S. D., Morrissey, L. W., DeMars, R., Welch, W. J., et al. (1990) Recognition by human V 7 9/V 8 2 T cells of a GroEL ho-molog on Daudi Burkitt's lymphoma cells. Science 250, 1269-1273.
190. Sturm, E., Braakman, E., Fisch, P., Vreugdenhil, R. J., Sondel, P., Bol-huis, R. L. (1990) Human V 7 9-V 8 2 T cell receptor-7 8 lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J. Immunol. 145, 3202-3208.
191. Tanaka, Y, Morita, C. T., Nieves, E., Brenner, M. B., Bloom, B. R. (1995) Natural and synthetic non-peptide antigens recognized by human 7 8 T cells. Nature 375, 155-158.
192. Bauer, S., Groh, V, Wu, J., Steinle, A, Phillips, J. H., Lanier, L. L., Spies, T. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729.
193. Bonneville, M., O'Brien, R. L., Born, W. K. (2010) 7Ô T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467-478.
194. Groh, V, Steinle, A., Bauer, S., Spies, T. (1998) Recognition of stress-induced MHC molecules by intestinal epithelial 7Ô T cells. Science 279, 1737-1740.
195. Maeurer, M. J., Martin, D., Walter, W., Liu, K, Zitvogel, L., Halusczcak, K, Rabinowich, H., Duquesnoy, R., Storkus, W., Lotze, M. T. (1996) Human intestinal VÔ1+ lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med. 183, 1681-1696.
196. Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., Wang, R. F. (2007) Tumor-infiltrating 7Ô T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27, 334-348.
197. Cordova, A., Toia, F., La Mendola, C, Orlando, V., Meraviglia, S., Rinaldi, G., Todaro, M., Cicero, G., Zichichi, L., Donni, P. L., Cac-camo, N-, Stassi, G., Dieli, F., Moschella, F. (2012) Characterization of human 7Ô T lymphocytes infiltrating primary malignant melanomas. PloS One, e49878.
198. Donia, M., Ellebaek, E., Andersen, M. H., Straten, P. T., Svane, I. M. (2012) Analysis of VÔ1 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 1, 1297-1304.
199. Lamb L. S., Jr., Musk, P., Ye, Z., van Rhee, F., Geier, S. S., Tong, J. J., King, K. M., Henslee-Downey, P. J. (2001) Human 7Ô(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an alloge-neic response. Bone Marrow Transplant. 27, 601-606.
200. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J., Ploegh, H. L. (2000) Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861-926.
201. Cooper, M. A, Elliott, J. M., Keyel, P. A, Yang, L., Carrero, J. A, Yokoyama, W. M. (2009) Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA 106, 1915-1919.
202. Sun, J. C, Lopez-Verges, S., Kim, C. C, DeRisi, J. L., Lanier, L. L. (2011) NK cells and immune "memory". J. Immunol. 186, 1891-1897.
203. Sun, J. C, Ma, A, Lanier, L. L. (2009) Cutting edge: IL-15-indepen-dent NK cell response to mouse cytomegalovirus infection. J. Immunol. 183, 2911-2914.
204. Guma, M., Angulo, A, Vilches, C, Gomez-Lozano, N., Malats, N., Lo-pez-Botet, M. (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104, 3664-3671.
205. Guma, M., Cabrera, C, Erkizia, I., Bofill, M., Clotet, B., Ruiz, L., Lo-pez-Botet, M. (2006) Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J. Infect. Dis. 194, 38-41.
206. Beziat, V., Liu, L., Malmberg, J. A, Ivarsson, M. A, Sohlberg, E., Bjork-lund, A T., Retiere, C, Sverremark-Ekstrom, E., Traherne, J., Ljung-man, P., Schaffer, M., Price, D. A, Trowsdale, J., Michaelsson, J., Ljunggren, H. G., Malmberg, K. J. (2013) NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121, 2678-2688.
207. Beziat, V., Dalgard, O., Asselah, T., Halfon, P., Bedossa, P., Boudifa, A, Hervier, B., Theodorou, L, Martinot, M., Debre, P., Bjorkstrom, N. K, Malmberg, K. J., Marcellin, P., Vieillard, V (2012) CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur. J. Immunol. 42, 447-457.
208. Delia Chiesa, M., Falco, M., Podesta, M., Locatelli, F., Moretta, L., Fras-soni, F., Moretta, A. (2012) Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood 119, 399-410.
209. Brunetta, E., Fogli, M., Varchetta, S., Bozzo, L., Hudspeth, K L., Mar-cenaro, E., Moretta, A, Mavilio, D. (2010) Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 24, 27-34.
210. Farnault, L., Chambost, H., Michel, G., Thuret, L, de Saint Basile, G., Fischer, A, Picard, C, Picard, C, Orlanducci, F., Farnarier, C, Moretta, A, Olive, D. (2013) Persistence of natural killer cells with expansion of a hypofunctional CD56-CD16 + KIR+NKG2C+ subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency. J. Allergy Clin. Immunol. 131, 1230-1233, 1233.el-1233.e2.
211. Foley, B., Cooley, S., Verneris, M. R, Pitt, M., Curtsinger, J., Luo, X., Lopez-Verges, S., Lanier, L. L., Weisdorf, D., Miller, J. S. (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119, 2665-2674.
212. Déchanet, J., Merville, P., Lim, A, Retiere, C, Pitard, V, Lafarge, X., Michelson, S., Meric, C, Hallet, M. M., Kourilsky, P., Potaux, L., Bonn-eville, M., Moreau, J. F. (1999) Implication of 7Ô T cells in the human immune response to cytomegalovirus. J. Clin. Invest. 103, 1437-1449.
213. Halary, F., Pitard, V., Dlubek, D., Krzysiek, R, de la Salle, H., Merville, P., Dromer, C, Emilie, D., Moreau, J. F., Dechanet-Merville, J. (2005) Shared reactivity of VÔ2(neg) 7Ô T cells against cytomegalovirus-in-fected cells and tumor intestinal epithelial cells. J. Exp. Med. 201, 1567-1578.
214. Pitard, V., Roumanes, D., Lafarge, X., Couzi, L., Garrigue, I., Lafon, M. E., Merville, P., Moreau, J. F., Dechanet-Merville, J. (2008) Long-term expansion of effector/memory VÔ2-7Ô T cells is a specific blood signature of CMV infection. Blood 112, 1317-1324.
215. Lafarge, X., Merville, P., Cazin, M. C, Berge, F., Potaux, L., Moreau, J. F., Dechanet-Merville, J. (2001) Cytomegalovirus infection in transplant recipients resolves when circulating 7Ô T lymphocytes expand, suggesting a protective antiviral role. J. Infect. Dis. 184, 533-541.
216. Vermijlen, D., Brouwer, M., Donner, C, Liesnard, C, Tackoen, M., Van Rysselberge, M., Twite, N., Goldman, M., Marchant, A, Willems, F. (2010) Human cytomegalovirus elicits fetal 7Ô T cell responses in utero. J. Exp. Med. 207, 807-821.
217. Couzi, L., Levaillant, Y, Jamai, A, Pitard, V., Lassalle, R, Martin, K, Garrigue, I., Hawchar, O., Siberchicot, F., Moore, N., Moreau, J. F., Dechanet-Merville, J., Merville, P. (2010) Cytomegalovirus-induced y8 T cells associate with reduced cancer risk after kidney transplantation. J. Am. Soc. Nephrol. 21, 181-188.
218. Devaud, C, Bilhere, E., Loizon, S., Pitard, V, Behr, C, Moreau, J. F., Dechanet-Merville, J., Capone, M. (2009) Antitumor activity of 7Ô T cells reactive against cytomegalovirus-infected cells in a mouse xeno-graft tumor model. Cancer Res. 69, 3971-3978.
219. Devaud, C, Rousseau, B., Netzer, S., Pitard, V, Paroissin, C, Khairal-lah, C, Costet, P., Moreau, J. F., Couillaud, F., Dechanet-Merville, J., Capone, M. (2013) Anti-metastatic potential of human VÔ1(+) 7Ô T cells in an orthotopic mouse xenograft model of colon carcinoma. Cancer Immunol. Immunother. 62, 1199-1210.
220. Elmaagacli, A H., Steckel, N. K, Koldehoff, M., Hegerfeldt, Y, Tren-schel, R, Ditschkowski, M., Christoph, S., Gromke, T., Kordelas, L., Ottinger, H. D., Ross, R S., Horn, P. A, Schnittger, S., Beelen, D. W. (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118, 1402-1412.
221. Green, M. L., Leisenring, W. M., Xie, H., Walter, R. B., Mielcarek, M., Sandmaier, B. M., Riddell, S. R, Boeckh, M. (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122, 1316-1324.
222. Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., Emerson, S. G. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415.
223. Asai, O-, Longo, D. L., Tian, Z. G., Hornung, R. L., Taub, D. D., Rusc-etti, F. W., Murphy, W. J. (1998) Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101, 1835-1842
224. Kruschinski, A, Moosmann, A, Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R, Blankenstein, T., Abken, H., Charo, J. (2008) Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. USA 105, 17481-17486.
225. Van der Veken, L. T., Hagedoorn, R S., van Loenen, M. M., Willemze, R, Falkenburg, J. H., Heemskerk, M. H. (2006) ex/3 T-cell receptor engineered 7Ô T cells mediate effective antileukemic reactivity. Cancer Res. 66, 3331-3337.
226. Deniger, D. C, Switzer, K, Mi, T., Maiti, S., Hurton, L., Singh, H., Huis, H., Olivares, S., Lee, D. A, Champlin, R E., Cooper, L. J. (2013) Bispecific T-cells expressing polyclonal repertoire of endogenous y8 T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol. Ther. 21, 638-647.
227. Hiasa, A., Nishikawa, H., Hirayama, M., Kitano, S., Okamoto, S., Chono, H., Yu, S. S., Mineno, J., Tanaka, Y, Minato, N., Kato, I., Shiku, H. (2009) Rapid ex/3 TCR-mediated responses in 7Ô T cells transduced with cancer-specific TCR genes. Gene Ther. 16, 620-628.
228. Pizzitola, I., Agostoni, V., Cribioli, E., Pule, M., Rousseau, R., Finney, H., Lawson, A, Biondi, A, Biagi, E., Marin, V. (2011) In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J. Immunother. 34, 469-479.
229. Themeli, M., Kloss, C. C, Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., Sadelain, M. (2013) Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. doi: 10.1038/nbt.2678. [Epub ahead of print].
230. Van der Veken, L. T., Coccoris, M., Swart, E., Falkenburg, J. H., Schumacher, T. N., Heemskerk, M. H. (2009) a /3 T cell receptor transfer to 7 ST cells generates functional effector cells without mixed TCR dimers in vivo. J. Immunol. 182, 164-170.
231. Marcenaro, E., Pesce, S., Sivori, S., Carlomagno, S., Moretta, L., Moretta, A. (2013) KIR2DSl-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood 121, 3396-3401.
232. Marcenaro, E., Cantoni, C, Pesce, S., Prato, C, Pende, D., Agaugue, S., Moretta, L., Moretta, A. (2009) Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with mono-cyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 114, 4108-4116.